Statins are promising anticancer agents that target the mevalonate pathway. Tumor cells are sensitive to depletion of mevalonate-derived products but this activity triggers a homeostatic feedback loop that blunts statin efficacy. We showed that dipyridamole inhibits this feedback response and potentiates statin antitumor activity. This study identifies statins plus dypridamole as a preclinically effective combination of approved agents.
CITATION STYLE
Pandyra, A., & Penn, L. Z. (2014). Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one. Molecular and Cellular Oncology, 1(4). https://doi.org/10.4161/23723548.2014.969133
Mendeley helps you to discover research relevant for your work.